Kalaris Therapeutics (KLRS) Liabilities and Shareholders Equity (2019 - 2026)

Kalaris Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $109.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 6.51% year-over-year to $109.8 million; the TTM figure through Mar 2026 stood at $405.6 million (up 11.79% YoY), while the FY2025 annual figure was $121.7 million, up 1875.59% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $109.8 million, down from $121.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $293.7 million in Q3 2022, with the low at $6.2 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $144.1 million (2024), against an average of $169.4 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 96.77% in 2024, then surged 1875.59% in 2025.
• Kalaris Therapeutics' Liabilities and Shareholders Equity stood at $277.1 million in 2022, then slumped by 31.14% to $190.8 million in 2023, then slumped by 96.77% to $6.2 million in 2024, then soared by 1875.59% to $121.7 million in 2025, then declined by 9.8% to $109.8 million in 2026.
• Business Quant data shows KLRS's Liabilities and Shareholders Equity at $109.8 million in Q1 2026, $121.7 million in Q4 2025, and $81.2 million in Q3 2025.